Evidence map›Paper›PMID 20051569›Full record

SynthesisJAMA2010

Antidepressant drug effects and depression severity: a patient-level meta-analysis.

Jay C Fournier, Robert J DeRubeis, Steven D Hollon, Sona Dimidjian, Jay D Amsterdam, Richard C Shelton, Jan Fawcett

2 registry-linked trialsAbstract readMeta-AnalysisReview
In one paragraph

Synthesis in JAMA, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 633 papers, 28 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
633citing papers in PubMed, 28 pooled it
168.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04211961 phase2completednot on this mapstarted 2021, after this paper: background citation

A Randomised Double-Blinded Placebo-Controlled Trial to Assess the Efficacy and Safety of Scopolamine Compared to Placebo in Individuals With Bipolar Disorder Who Are Experiencing a Depressive Episode

TypeinterventionalSponsorDr. Brian HallahanRan2021 to 2024Enrolled55ConditionsBipolar Disorder DepressionArmsPlacebo / Saline, Scopolamine
NCT04356274 naenrolling by invitationnot on this mapstarted 2019, after this paper: background citation

Participatory System Dynamics vs Audit and Feedback: A Cluster Randomized Trial of Mechanisms of Implementation Change to Expand Reach of Evidence-based Addiction and Mental Health Care

TypeinterventionalSponsorPalo Alto Veterans Institute for ResearchRan2019 to 2027Enrolled720ConditionsPTSD, Depression, Alcohol Use Disorder, Opioid Use DisorderArmsParticipatory System Dynamics (PSD), Audit and Feedback (AF)
3 · Its place in the literature

Who cites it

633 citing papers in PubMed, 28 syntheses or guidelines pooled it, 1,992 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Effects and safety ofFrontiers in pharmacology · 2024
    Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Guideline
  18. Pooled it
  19. Pooled it
  20. Pooled it

573 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Jay C FournierDepartment of Psychology, University of Pennsylvania, 3720 Walnut St, Philadelphia, PA 19104, USA. jcf@sas.upenn.edu
Robert J DeRubeis
Steven D Hollon
Sona Dimidjian
Jay D Amsterdam
Richard C Shelton
Jan Fawcett
University of Pennsylvania · USVanderbilt University · USUniversity of Colorado Boulder · USUniversity of New Mexico · US

Funding

PREVENTION OF RECURRENCE IN DEPRESSION WITH DRUGS AND CTR01MH060998 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI DERUBEIS, ROBERT J · 2002 to 2011
$6.5M
Prevention of Recurrence in Depression with Drugs and CTK02MH001697 · NIMH · VANDERBILT UNIVERSITY · PI HOLLON, STEVEN DENNIS · 2000 to 2009
$1.2M
MOLECULAR NEUROBIOLOGY OF DEPRESSIONK24MH001741 · NIMH · VANDERBILT UNIVERSITY · PI SHELTON, RICHARD CHARLES · 1999 to 2003
$425k
COGNITIVE THERAPY AND PHARMACOTHERAPY FOR DEPRESSIONR10MH055877 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI DERUBEIS, ROBERT J · 1996 to 2000
$314k
COGNITIVE THERAPY AND PHARMACOTHERAPY FOR DEPRESSIONR10MH055875 · NIMH · VANDERBILT UNIVERSITY · PI HOLLON, STEVEN D · 1996 to 2000
$231k
NIMH NIH HHS K02 MH001697NIMH NIH HHS K02 MH01697NIMH NIH HHS K24 MH001741NIMH NIH HHS K24 MH01741NIMH NIH HHS R01 MH060998NIMH NIH HHS R10 MH055875NIMH NIH HHS R10 MH055877NIMH NIH HHS R10 MH50129NIMH NIH HHS R10 MH55875
6 · The paper itself

Abstract

contextAntidepressant medications represent the best established treatment for major depressive disorder, but there is little evidence that they have a specific pharmacological effect relative to pill placebo for patients with less severe depression.

objectiveTo estimate the relative benefit of medication vs placebo across a wide range of initial symptom severity in patients diagnosed with depression. DATA SOURCES: PubMed, PsycINFO, and the Cochrane Library databases were searched from January 1980 through March 2009, along with references from meta-analyses and reviews. STUDY SELECTION: Randomized placebo-controlled trials of antidepressants approved by the Food and Drug Administration in the treatment of major or minor depressive disorder were selected. Studies were included if their authors provided the requisite original data, they comprised adult outpatients, they included a medication vs placebo comparison for at least 6 weeks, they did not exclude patients on the basis of a placebo washout period, and they used the Hamilton Depression Rating Scale (HDRS). Data from 6 studies (718 patients) were included. DATA EXTRACTION: Individual patient-level data were obtained from study authors.

resultsMedication vs placebo differences varied substantially as a function of baseline severity. Among patients with HDRS scores below 23, Cohen d effect sizes for the difference between medication and placebo were estimated to be less than 0.20 (a standard definition of a small effect). Estimates of the magnitude of the superiority of medication over placebo increased with increases in baseline depression severity and crossed the threshold defined by the National Institute for Clinical Excellence for a clinically significant difference at a baseline HDRS score of 25.

conclusionsThe magnitude of benefit of antidepressant medication compared with placebo increases with severity of depression symptoms and may be minimal or nonexistent, on average, in patients with mild or moderate symptoms. For patients with very severe depression, the benefit of medications over placebo is substantial.

Indexed as

AdultAntidepressive AgentsDepressionHumansMajor Depressive DisorderPlacebo EffectRandomized Controlled Trials as TopicTreatment OutcomeAntidepressive Agents

Identifiers

PMID20051569
PMCPMC3712503
OpenAlexW2004762037

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.